You are here

  • Home
  • Archive
  • Volume 81, Issue 5
  • Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Citation Tools

Article menu
Download PDFPDF
Epidemiology
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Bonelli M, Mrak D, Tobudic S, et al
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial
Annals of the Rheumatic Diseases 2022;81:687-694.